1. Home
  2. SXTC vs RNTX Comparison

SXTC vs RNTX Comparison

Compare SXTC & RNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo China SXT Pharmaceuticals Inc.

SXTC

China SXT Pharmaceuticals Inc.

HOLD

Current Price

$1.99

Market Cap

92.9M

Sector

Health Care

ML Signal

HOLD

Logo Rein Therapeutics Inc.

RNTX

Rein Therapeutics Inc.

HOLD

Current Price

$0.84

Market Cap

89.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SXTC
RNTX
Founded
2005
2001
Country
China
United States
Employees
N/A
10
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
92.9M
89.0M
IPO Year
2017
N/A

Fundamental Metrics

Financial Performance
Metric
SXTC
RNTX
Price
$1.99
$0.84
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$10.00
AVG Volume (30 Days)
42.2K
579.2K
Earning Date
08-19-2019
05-15-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.03
$0.83
52 Week High
$6.98
$2.18

Technical Indicators

Market Signals
Indicator
SXTC
RNTX
Relative Strength Index (RSI) 40.74 38.63
Support Level $1.95 N/A
Resistance Level $2.21 $1.05
Average True Range (ATR) 0.32 0.08
MACD -0.05 -0.01
Stochastic Oscillator 27.36 2.32

Price Performance

Historical Comparison
SXTC
RNTX

About SXTC China SXT Pharmaceuticals Inc.

China SXT Pharmaceuticals Inc is a pharmaceutical company that is focused on the research, development, manufacture, marketing, and sales of Traditional Chinese Medicine Pieces (TCMP), particularly TCMP (Directed-oral TCMP and After-soaking TCMP), which is a sort of Traditional Chinese Medicine (TCM) that has been processed to be ready for use without decoction. Geographically, the firm generates its revenue from the People's Republic of China.

About RNTX Rein Therapeutics Inc.

Rein Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications with no approved or limited effective treatments. Its pipeline includes: LTI-03, a peptide, for placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis, that has demonstrated the ability to protect healthy lung epithelial cells and reduce pro-fibrotic signaling; LTI-01, a proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment.

Share on Social Networks: